Abstract
The Role of Chemotherapy in Triple Negativ Breast Cancer
Highlights
Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3-5 years but drops sharply and substantially below after those hormone-positive breast cancers
Tumors that are ER, PgR, and HER2-negative are known as triple-negative BCs (TNBCs) and account for about 12-20% of Breast cancer (BC) [4]
These tumors develop earlier in life, especially in premenopausal women, and have a poorer prognosis than the other types of BC due to the higher aggressiveness. These factors may be a major reason for the high-risk relapse, and shorter progression-free survival (PFS)
Summary
Triple-negative breast cancers have a relapse pattern that is very different from hormone-positive breast cancers: the risk of relapse is much higher for the first 3-5 years but drops sharply and substantially below after those hormone-positive breast cancers. Data on the use of gemsitabini in metastatic triple-negative BCs are analyzed, concluding they are effective in any clinical setting (neoadjuvant, adjuvant, and metastatic). The available data show the clinical potential of based combinations in terms of long-duration response, increased survival, and better quality of life of patients with triple-negative metastatic BC. BC in the territory of the Republic among urban and rural population by determining the average annual intensive and standardized incidence rates for the years 2008-2010. On the territory of the Republic those in urban areas more often suffer from cancer of the breast (13,2%x>00) than rural (8,5%00) [2,3]. The greatest proportion is malignant breast tumors (20.4%) [3,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
